Concord Drugs Ltd
₹ 77.0
-2.88%
17 Sep
- close price
About
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
Key Points
- Market Cap ₹ 101 Cr.
- Current Price ₹ 77.0
- High / Low ₹ 92.5 / 61.0
- Stock P/E 49.7
- Book Value ₹ 36.8
- Dividend Yield 0.00 %
- ROCE 5.19 %
- ROE 2.52 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -9.31%
- The company has delivered a poor sales growth of 8.12% over past five years.
- Company has a low return on equity of 1.63% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 75.85 | 83.37 | |
| 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 71.61 | 77.81 | |
| Operating Profit | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.24 | 5.56 |
| OPM % | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 5.59% | 6.67% |
| 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | |
| Interest | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.46 | 1.39 |
| Depreciation | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.36 | 1.34 |
| Profit before tax | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 1.45 | 2.85 |
| Tax % | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | 28.28% | |
| 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 1.04 | 2.04 | |
| EPS in Rs | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.79 | 1.59 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 8% |
| 3 Years: | 14% |
| TTM: | 90% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | 21% |
| 3 Years: | 5% |
| TTM: | 423% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 24% |
| 3 Years: | 32% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 | 13.18 |
| Reserves | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 35.34 |
| 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 12.52 | |
| 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 10.82 | |
| Total Liabilities | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 71.86 |
| 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.55 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 | 2.43 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 | 1.62 |
| 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 56.26 | |
| Total Assets | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 71.86 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.75 | 3.05 | 1.70 | 6.88 | 1.19 | 2.48 | 1.62 | 0.77 | 2.24 | 1.96 | 2.04 | -6.22 | |
| -1.10 | 0.23 | -1.04 | -2.21 | -0.34 | -0.84 | -3.67 | -2.44 | -2.27 | -1.21 | -2.32 | -1.13 | |
| -0.70 | -3.42 | -3.94 | -4.80 | -0.73 | -1.79 | 2.07 | 1.68 | 0.05 | -0.69 | 0.26 | 7.51 | |
| Net Cash Flow | -0.06 | -0.14 | -3.28 | -0.13 | 0.12 | -0.15 | 0.02 | 0.01 | 0.03 | 0.06 | -0.02 | 0.16 |
| Free Cash Flow | 0.65 | 3.28 | 0.66 | 4.60 | 0.85 | 1.63 | -2.05 | -1.69 | 1.38 | 0.94 | -0.29 | -7.39 |
| CFO/OP | 33% | 51% | 38% | 152% | 36% | 78% | 65% | 26% | 60% | 59% | 59% | -137% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 | 135.37 |
| Inventory Days | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 | 102.82 |
| Days Payable | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 | 33.73 |
| Cash Conversion Cycle | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 | 204.45 |
| Working Capital Days | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 144.20 | 147.83 |
| ROCE % | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% | 5.19% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure on Fixed Assets Rs. Lakhs |
|
|||||||||
| Purchases from Related Parties Rs. Lakhs |
||||||||||
| Sales to Related Parties Rs. Lakhs |
||||||||||
| Number of Employees count |
||||||||||
| Capital Work-in-Progress Rs. Lakhs |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Copies of News paper publications of the Notice of the 31st AGM to be held on 30.09.2026
-
Letter To Shareholders
- 31st AGM scheduled for 30 September 2026; annual report FY2025-26 web link shared.
- Intimation Of Record Date For 31St AGM
- Reg. 34 (1) Annual Report.
- 31St AGM
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
CDL is a Telangana based company which is in the business of manufacturing licensed bulk drugs and active pharmaceutical intermediates on the approved formulations. Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.